SCHEMBL21483744

SCHEMBL21483744

CC(C)(O)Cc1ccc(OCCBr)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
ACACB O00763 2/20 0.40
EBP Q15125 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
MMP1 P03956 2/20 0.38
MMP9 P14780 2/20 0.38
MMP13 P45452 2/20 0.38
CYP3A4 P08684 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PPARG P37231 3/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
PSMB1 P20618 1/20 0.36
PSMB5 P28074 1/20 0.36
PSMB2 P49721 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL358896 0.84 CYP3A4 (0.53) HRH3ALDH1A1LMNAACACBCYP3A4
SCHEMBL9027655 0.79 NR5A1 (0.59) ALDH1A1LMNACYP3A4SMN1; SMN2
SCHEMBL4538628 0.79 EBP (0.46) HRH3LMNAEBPSIGMAR1MMP1
SCHEMBL20843304 0.78 LMNA (0.41) HRH3ALDH1A1LMNAACACBSMN1; SMN2
SCHEMBL21483685 0.77 CASR (0.41) LMNA
SCHEMBL18428506 0.77 LTA4H (0.43) ALDH1A1CYP3A4SMN1; SMN2PPARG
SCHEMBL8140756 0.76 NPC1 (0.47) ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL11132376 0.75 IDO1 (0.50) ALDH1A1CYP3A4SMN1; SMN2
SCHEMBL5361488 0.75 HRH3 (0.50) HRH3ALDH1A1SMN1; SMN2PPARGPPARA
SCHEMBL2412878 0.75 LMNA (0.55) HRH3ALDH1A1LMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11447485-B2 Class of bifunctional compounds with quanternary ammonium salt structure BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) 2022-09-20 US disclosed
CN-110087729-B Bifunctional compound with quaternary ammonium salt structure 北京硕佰医药科技有限责任公司 2022-04-05 CN disclosed
EP-3556435-B1 CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) 2020-10-28 EP disclosed
EP-3556435-A1 CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE Beijing Showby Pharmaceutical Co., Ltd. (CN) 2019-10-23 EP disclosed
CN-110087729-A One kind has the dual-function compound of quaternary ammonium salt structure 北京硕佰医药科技有限责任公司 2019-08-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11447485-B2 Class of bifunctional compounds with quanternary ammonium salt structure AGTR2, AGTR1, ADRB2 HRH3 332/4885ALDH1A1 2715/4885LMNA 2541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.